LPC
Lion Point Capital Portfolio holdings
AUM
$14.7M
This Quarter Return
+4.76%
1 Year Return
+16.78%
3 Year Return
+52.25%
5 Year Return
+189.95%
10 Year Return
–
AUM
$31.9M
AUM Growth
+$31.9M
(-39%)
Cap. Flow
-$1.98M
Cap. Flow
% of AUM
-6.21%
Top 10 Holdings %
Top 10 Hldgs %
81.82%
Holding
32
New
1
Increased
5
Reduced
5
Closed
4
Top Buys
| 1 |
BridgeBio Pharma
BBIO
|
$1.24M |
| 2 |
Mineralys Therapeutics
MLYS
|
$222K |
| 3 |
Geron
GERN
|
$127K |
| 4 |
Neurocrine Biosciences
NBIX
|
$117K |
| 5 |
Milestone Pharmaceuticals
MIST
|
$52.8K |
Top Sells
| 1 |
Ardelyx
ARDX
|
$1.41M |
| 2 |
Humacyte
HUMA
|
$731K |
| 3 |
Travere Therapeutics
TVTX
|
$601K |
| 4 |
Kiniksa Pharmaceuticals
KNSA
|
$485K |
| 5 |
Replimune Group
REPL
|
$347K |
Sector Composition
| 1 | Healthcare | 87.47% |
| 2 | Financials | 2.69% |
| 3 | Consumer Discretionary | 1.75% |
| 4 | Technology | 0.14% |
| 5 | Energy | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
iShares Russell 2000 ETF
IWM
$67B
| – | – |
0
| – | – |
|
27
Mirum Pharmaceuticals
MIRM
$3.71B
| – | – |
0
| – | – |
|
|
28
Replimune Group
REPL
$422M
| – | – |
-42,500
| Closed | -$347K |
|
29
Semtech
SMTC
$5.04B
| – | – |
-14
| Closed | -$385 |
|
|
30
Travere Therapeutics
TVTX
$1.56B
| – | – |
-78,000
| Closed | -$601K |
|
31
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – |
0
| – | – |
|